Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety roll-over study of everolimus in TSC with refractory seizures (post-CRAD001M2304)
2016-002977-37Phase 3Unknown
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of everolimus in tuberous sclerosis complex (TSC) and refractory epilepsy associated with tuberous sclerosis complex (TSC-RE), sponsored by Novartis. Primary endpoint: Frequency and severity of AEs/SAEs. Status: unknown.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)refractory epilepsy associated with tuberous sclerosis complex (TSC-RE)
Beyond the preview
Go deeper on 2016-002977-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002977-37.